Medical Technology School of Xuzhou Medical University, Xuzhou, Jiangsu, 221004, P.R. China
Department of Stem Cell Biology, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan
Curr Stem Cell Res Ther. 2020;15(8):649-660. doi: 10.2174/1574888X15666200102103755.
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality globally, and traditional pharmaceutical and surgical interventions delay the progression of CVDs. Recently, stem cell therapy has emerged as a promising candidate for treating and preventing heart failure. Increasing efforts have been devoted towards the exploration and identification of potential cell types to repair the injured heart, such as skeletal myoblasts, embryonic, induced pluripotent, bone marrowderived, mesenchymal, and resident cardiac stem cells. In addition, direct reprogramming of cardiac fibroblasts into cardiomyocytes represents a novel approach to cardiac regeneration. Herein, we summarize the recent progress in the use of various cell types for cardiac regeneration and discuss major challenges and future perspectives of cell-based therapies for CVDs.
心血管疾病(CVDs)是全球发病率和死亡率的主要原因,传统的药物和手术干预措施延缓了 CVD 的进展。最近,干细胞疗法作为治疗和预防心力衰竭的一种有前途的方法已经出现。人们越来越努力地探索和确定潜在的细胞类型来修复受损的心脏,如骨骼肌母细胞、胚胎、诱导多能、骨髓衍生、间充质和驻留心脏干细胞。此外,将心脏成纤维细胞直接重编程为心肌细胞代表了心脏再生的一种新方法。本文总结了目前使用各种细胞类型进行心脏再生的最新进展,并讨论了基于细胞的 CVD 治疗的主要挑战和未来展望。